MGMT and central nervous system cancer: Indeed, a recent study of adult glioma highlights the prognostic and predictive impact of key molecular alterations, such as IDH mutation and MGMT promotor methylation status [25], suggesting using a molecular approach to guide therapy is clinically relevant and feasible.